Gabriel Pet (544108)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue and profit explosion: sales growth 895.44%, profit growth 966.67%, with latest quarter sales of ₹55 Cr and net profit of ₹2 Cr.
• If the latest quarter annualizes to ~₹8 Cr profit, the forward P/E is roughly 17x versus the trailing P/E of 38.13x.
• Piotroski F-Score of 7/9 suggests improving profitability, leverage, and operating efficiency.
• PEG of 0.04 indicates the market is pricing in much lower growth relative to the recent earnings surge.
• Small market cap of ₹137 Cr leaves room for expansion if the growth proves durable.

Concerns

• ROCE is only 7.62%, signaling weak capital efficiency and no clear evidence of a durable moat.
• Trailing P/E of 38.13 is expensive, and the huge growth percentages come from a very small base.
• Zero dividend yield means no cash return to minority shareholders.
• Critical data is missing: book value, debt/equity, promoter holding, 52-week range, and FairStock Score is insufficient.

AI Analysis

At first glance, Gabriel Pet looks like a hyper-growth story. Sales grew 895% and profits 966%, and the latest quarter shows ₹55 Cr in sales with ₹2 Cr in net profit. At ₹183, the market cap is only ₹137 Cr, so if that quarterly profit were annualised, you get roughly ₹8 Cr and a forward P/E near 17. That sounds reasonable—but Warren Buffett would remind me that growth only matters if the business earns good returns on capital. ROCE is just 7.62%, which is mediocre. I want a machine that converts retained capital into high returns; this does not yet prove that. The Piotroski F-Score of 7 out of 9 is a positive sign. It suggests the company's financial health has improved. But I have no book value, no debt-to-equity, no promoter holding, no 52-week range, and the FairStock Score says insufficient data. Benjamin Graham taught me to demand adequate information before I commit capital. A 38.13 trailing P/E is not cheap, and the so-called PEG of 0.04 is built on extraordinary growth numbers from a small base. One bad quarter will change that picture. I like small, nimble industrial product companies in India when they have a clear moat. Here I see explosive revenue and profit growth, but I don't see evidence of pricing power or a durable competitive advantage. Zero dividend tells me all earnings are being reinvested—or maybe not returned—and I cannot evaluate management without more ownership data. So it is a fast grower, not a stalwart. I would watch whether quarterly sales and profits sustain, whether ROCE climbs past 15%, and whether the company finally gives full details on debt, book value and promoter holding. Until then, this is a 'too hard' pile for me, not a foundation position.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer